Literature DB >> 12965058

Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function.

David I Lee1, Cassio R Andreoni, Jamil Rehman, Jaime Landman, Maged Ragab, Yan Yan, Cathy Chen, Alan Shindel, William Middleton, Arieh Shalhav, Elspeth M McDougall, Ralph V Clayman.   

Abstract

BACKGROUND AND
PURPOSE: In patients with autosomal dominant polycystic kidney disease (ADPKD), laparoscopic cyst decortication (LCD) has been proposed as a means to relieve chronic cyst-related pain. We present our 7-year experience with LCD for ADPKD with regard to pain relief, hypertension, and renal function. PATIENTS AND METHODS: Between August 1994 and February 2001, 29 ADPKD patients with chronic pain (N=29), hypertension (N=21), and renal insufficiency (N=10) underwent 35 LCD procedures. Every detectable cyst within 2 mm of the renal surface was treated. Pain relief was assessed using a pain analog scale; relative pain relief (RPR) equaled (preoperative pain score) - (postoperative pain score)/(preoperative pain score). Hypertension was evaluated using the antihypertensive therapeutic index (ATI): [(dose of blood pressure medication 1/max dose 1) + (dose med 2/max dose 2) + etc.] x 10. Renal function was assessed using the Cockcroft and Gault formula for creatinine clearance.
RESULTS: The mean operating room time was 4.9 hours (range 2.6-6.6 hours) with no conversions to open surgery. An average of 220 cysts (range 4-692) were treated per patient. The mean follow-up was 32.3 months (range 6-72 months). The RPR was 58%, 47%, and 63% at 12, 24, and 36 months, respectively. At 12, 24, and 36 months, 73%, 52%, and 81% of patients, respectively, noted >50% improvement in their pain compared with the preoperative situation. Five patients became normotensive, and patients improved their ATI by an average of 49% (range 11%-93%). However, six patients had worsening hypertension, with an ATI increase averaging 53% (range 11%-122%), and one patient who was not hypertensive preoperatively has since developed hypertension. The creatinine clearance changed +4%, +7%, and -2% at 12, 24, and 36 months, respectively. Only one patient had a >20% increase in creatinine clearance. The only patients with a >20% decrease in creatinine clearance were those who had a creatinine clearance <30 mg/dL preoperatively (average decrease 34% [range 20%-51%]).
CONCLUSIONS: For ADPKD patients with debilitating pain, extensive LCD can provide durable relief. In the majority of patients with pain and hypertension, a marked improvement in blood pressure also occurs. Cyst decortication was not associated with worsening renal function; indeed, renal function remained largely unchanged over the 3-year follow-up period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965058     DOI: 10.1089/089277903767923100

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  12 in total

1.  Long-term functional results of aspiration and sclerotherapy with ethanol in patients with autosomal dominant polycystic kidney disease: a non-randomized pilot clinical study.

Authors:  Eyüp Veli Küçük; Ahmet Tahra; Ahmet Bindayi; Ferhat Yakup Suçeken; Fikret Fatih Önol; Uğur Boylu
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

Review 2.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

3.  Hypertension and hydronephrosis: rapid resolution of high blood pressure following relief of bilateral ureteric obstruction.

Authors:  Anil Chalisey; Mahzuz Karim
Journal:  J Gen Intern Med       Date:  2012-08-10       Impact factor: 5.128

4.  Hyperbaric oxygen therapy in a patient with autosomal dominant polycystic kidney disease with a perinephritic abscess.

Authors:  Jorge Vega; Helmuth Goecke; Francisco Manriquez; Carlos Escobar; Max Escobar; Christian Videla; Mario Santamarina; Carlos Echeverria; Francisco Javier Guarda
Journal:  Clin Exp Nephrol       Date:  2010-10-01       Impact factor: 2.801

Review 5.  Surgical cyst decortication in autosomal dominant polycystic kidney disease.

Authors:  Melissa Millar; Youssef S Tanagho; Mohammed Haseebuddin; Ralph V Clayman; Sam B Bhayani; R Sherburne Figenshau
Journal:  J Endourol       Date:  2013-02-05       Impact factor: 2.942

Review 6.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

7.  Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Authors:  Dana C Miskulin; Kaleab Z Abebe; Arlene B Chapman; Ronald D Perrone; Theodore I Steinman; Vicente E Torres; K Ty Bae; William Braun; Franz T Winklhofer; Marie C Hogan; Fred Rahbari-Oskoui; Charity G Moore; Michael F Flessner; Robert W Schrier
Journal:  Am J Kidney Dis       Date:  2013-11-01       Impact factor: 8.860

Review 8.  Taking the side of transperitoneal access for surgery in upper urinary tract.

Authors:  Mohamad E Allaf; Sam B Bhayani; Louis R Kavoussi
Journal:  Curr Urol Rep       Date:  2004-04       Impact factor: 2.862

9.  Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.

Authors:  Christian R Halvorson; Matthew S Bremmer; Stephen C Jacobs
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-06-24

Review 10.  The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.

Authors:  Myrte K Neijenhuis; Wietske Kievit; Ronald D Perrone; Jeff A Sloan; Patricia Erwin; Mohammad Hassan Murad; Tom J G Gevers; Marie C Hogan; Joost P H Drenth
Journal:  BMC Nephrol       Date:  2017-05-25       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.